Last reviewed · How we verify

Ferric Derisomaltose Injection

Hallym University Medical Center · Phase 3 active Small molecule

Ferric Derisomaltose Injection is a Iron replacement agent Small molecule drug developed by Hallym University Medical Center. It is currently in Phase 3 development for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or unresponsive to oral iron therapy. Also known as: iron isomaltoside, Monoferric, Monofer.

Ferric derisomaltose is an iron replacement therapy that delivers ferric iron complexed with derisomaltose to replenish depleted iron stores.

Ferric derisomaltose is an iron replacement therapy that delivers ferric iron complexed with derisomaltose to replenish depleted iron stores. Used for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or unresponsive to oral iron therapy.

At a glance

Generic nameFerric Derisomaltose Injection
Also known asiron isomaltoside, Monoferric, Monofer
SponsorHallym University Medical Center
Drug classIron replacement agent
TargetIron metabolism pathway
ModalitySmall molecule
Therapeutic areaHematology
PhasePhase 3

Mechanism of action

Ferric derisomaltose is a ferric iron carbohydrate complex designed for intravenous administration. The derisomaltose ligand stabilizes the ferric iron and facilitates cellular uptake via transferrin-independent pathways, allowing rapid iron delivery to iron-deficient tissues and bone marrow for hemoglobin synthesis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ferric Derisomaltose Injection

What is Ferric Derisomaltose Injection?

Ferric Derisomaltose Injection is a Iron replacement agent drug developed by Hallym University Medical Center, indicated for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or unresponsive to oral iron therapy.

How does Ferric Derisomaltose Injection work?

Ferric derisomaltose is an iron replacement therapy that delivers ferric iron complexed with derisomaltose to replenish depleted iron stores.

What is Ferric Derisomaltose Injection used for?

Ferric Derisomaltose Injection is indicated for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or unresponsive to oral iron therapy.

Who makes Ferric Derisomaltose Injection?

Ferric Derisomaltose Injection is developed by Hallym University Medical Center (see full Hallym University Medical Center pipeline at /company/hallym-university-medical-center).

Is Ferric Derisomaltose Injection also known as anything else?

Ferric Derisomaltose Injection is also known as iron isomaltoside, Monoferric, Monofer.

What drug class is Ferric Derisomaltose Injection in?

Ferric Derisomaltose Injection belongs to the Iron replacement agent class. See all Iron replacement agent drugs at /class/iron-replacement-agent.

What development phase is Ferric Derisomaltose Injection in?

Ferric Derisomaltose Injection is in Phase 3.

What are the side effects of Ferric Derisomaltose Injection?

Common side effects of Ferric Derisomaltose Injection include Injection site reactions, Headache, Nausea, Dizziness, Hypersensitivity reactions.

What does Ferric Derisomaltose Injection target?

Ferric Derisomaltose Injection targets Iron metabolism pathway and is a Iron replacement agent.

Related